Brian J. Long
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Estrogen and related hormone effects, Cancer Immunotherapy and Biomarkers, Hippo pathway signaling and YAP/TAZ, interferon and immune responses, Melanoma and MAPK Pathways
Most-Cited Works
- → Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors(2013)676 cited
- → An orally available non-nucleotide STING agonist with antitumor activity(2020)621 cited
- → Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression(2015)271 cited
- → Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy(2013)169 cited
- Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.(2003)
- → The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling(2005)161 cited
- → Aromatase and COX-2 expression in human breast cancers(2001)150 cited